Skip to main content
Premium Trial:

Request an Annual Quote

HTG Receives Phase II SBIR Award to Continue Development of Sequencing Products

NEW YORK (GenomeWeb News) – The National Human Genome Research Institute has awarded HTG Molecular Diagnostics a $1.01 million award to continue development of targeted sequencing products, the Tucson, Ariz.-based company said today.

The one-year Phase II Small Business Innovation Research grant allows HTG to continue work that was carried out under a $599,000 Phase I SBIR grant to the company for the Nuclease Robe Mediated Sequencing Project (HTG EdgeSeq), which seeks to develop targeted sequencing products using HTG's core RNA analysis technology.

HTG said it recently completed the first two years of the HTG EdgeSeq project under the Phase I grant. In addition to the Phase II award, the company is eligible for a $587,000 award for an additional year of the program.

Products developed under the program will enable the quantitative analysis of miRNA and mRNA targes from very small samples with "virtually unlimited multiplexing options," HTG said.

HTG CEO T. J. Johnson said in a statement, "This award will help fund and accelerate our development efforts as we move from feasibility to a fully integrated solution with our 100 percent extraction-free chemistry and the HTG Edge System automation."